Peptide vaccine with antibody therapy for prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of a personalized peptide vaccine and an antibody therapy for men with prostate cancer that has returned after initial treatment. The goal is to see if this approach can control the cancer without needing stronger hormone therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 to 80.
- You have prostate cancer that was previously treated with surgery or radiation but has now returned (rising PSA).
- A PET scan shows the cancer has not spread to distant parts of the body.
- Your cancer is not growing too quickly (based on PSA doubling time and Gleason score).
- You have not used hormone therapy, or if you did, your testosterone has returned to normal.
- You are otherwise healthy enough for daily activities (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two treatments for men with prostate cancer that has spread to a small number of sites: a radioactive injection (177Lu-PSMA-617) that targets cancer cells, plus hormone-blocking medication. The goal is to control the cancer and delay progression.
This trial tests an experimental vaccine (2141-V11) combined with standard hormone therapy and an anti-androgen drug before prostate removal surgery. It aims to see if the combination can help the immune system fight the cancer more effectively.
This study tests an experimental vaccine that may help your immune system fight prostate cancer cells. If you have low- or intermediate-risk prostate cancer and are under active surveillance, this vaccine might slow or prevent the cancer from growing.
This trial studies a treatment that targets a protein called PSMA in people with prostate cancer. It may help shrink or control the cancer and is being tested in different risk groups and stages of disease.
This study combines two treatments: pembrolizumab, which helps your immune system fight cancer, and a targeted radioactive medicine (177Lu-PSMA-617) that seeks out and damages prostate cancer cells. It may help men whose prostate cancer has spread despite initial hormone therapy.
This trial uses a special PET/MR scan to help doctors aim stereotactic radiation more precisely for certain higher-risk or unfavorable intermediate prostate cancers. It studies whether this targeted approach can safely treat the prostate (and specific areas needing extra treatment) without spreading to the body.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.